To better distinguish the impact of tumor-directed versus immune-directed activity of a CD38-directed AttenukineTM, different immunocompetent animal strains and tumor models (expressing human or mouse CD38) were used in in vivo studies. The gene discussed is CD38; the disease is neoplasm.